Synthesis and Antiproliferative Insights of Lipophilic Ru(II)-Hydroxy Stearic Acid Hybrid Species

Metallodrugs represent a combination of multifunctionalities that are present concomitantly and can act differently on diverse biotargets. Their efficacy is often related to the lipophilic features exhibited both by long carbo-chains and the phosphine ligands. Three Ru(II) complexes containing hydroxy stearic acids (HSAs) were successfully synthesized in order to evaluate possible synergistic effects between the known antitumor activity of HSA bio-ligands and the metal center. HSAs were reacted with [Ru(H)2CO(PPh3)3] selectively affording O,O-carboxy bidentate complexes. The organometallic species were fully characterized spectroscopically using ESI-MS, IR, UV-Vis, and NMR techniques. The structure of the compound Ru-12-HSA was also determined using single crystal X-ray diffraction. The biological potency of ruthenium complexes (Ru-7-HSA, Ru-9-HSA, and Ru-12-HSA) was studied on human primary cell lines (HT29, HeLa, and IGROV1). To obtain detailed information about anticancer properties, tests for cytotoxicity, cell proliferation, and DNA damage were performed. The results demonstrate that the new ruthenium complexes, Ru-7-HSA and Ru-9-HSA, possess biological activity. Furthermore, we observed that the Ru-9-HSA complex shows increased antitumor activity on colon cancer cells, HT29.

[1]  A. Jemal,et al.  Cancer statistics, 2023 , 2023, CA: a cancer journal for clinicians.

[2]  A. Pratesi,et al.  Highlights of New Strategies to Increase the Efficacy of Transition Metal Complexes for Cancer Treatments , 2022, Molecules.

[3]  L. Lilge,et al.  Ru(II) CONTAINING PHOTOSENSITIZERS FOR PHOTODYNAMIC THERAPY: A CRITIQUE ON REPORTING AND AN ATTEMPT TO COMPARE EFFICACY. , 2022, Coordination chemistry reviews.

[4]  K. Lillemoe,et al.  Institutional Surgical Response and Associated Volume Trends Throughout the COVID-19 Pandemic and Postvaccination Recovery Period , 2022, JAMA network open.

[5]  D. Musumeci,et al.  Bioengineered lipophilic Ru(III) complexes as potential anticancer agents. , 2022, Biomaterials advances.

[6]  R. Eswaramoorthy,et al.  Metal Complexes in Target-Specific Anticancer Therapy: Recent Trends and Challenges , 2022, Journal of Chemistry.

[7]  N. Calonghi,et al.  Effects of Regioisomerism on the Antiproliferative Activity of Hydroxystearic Acids on Human Cancer Cell Lines , 2022, Molecules.

[8]  A. Jemal,et al.  Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.

[9]  C. Giorgi,et al.  Combination of light and Ru(II) polypyridyl complexes: Recent advances in the development of new anticancer drugs , 2022, Coordination Chemistry Reviews.

[10]  G. Gasser,et al.  Recent Approaches towards the Development of Ru(II) Polypyridyl Complexes for Anticancer Photodynamic Therapy. , 2021, Chimia.

[11]  A. Jemal,et al.  Association of the COVID-19 Pandemic with Patterns of Statewide Cancer Services. , 2021, Journal of the National Cancer Institute.

[12]  I. Marzo,et al.  Multifunctional Heterometallic IrIII−AuI Probes as Promising Anticancer and Antiangiogenic Agents , 2021, Chemistry.

[13]  M. Contel,et al.  Exploring the Potential of Metallodrugs as Chemotherapeutics for Triple Negative Breast Cancer. , 2021, Chemistry.

[14]  Riccardo Tarroni,et al.  Ruthenium–Thymine Acetate Binding Modes: Experimental and Theoretical Studies , 2021, Applied Sciences.

[15]  W. D. De Vos,et al.  Auranofin reveals therapeutic anticancer potential by triggering distinct molecular cell death mechanisms and innate immunity in mutant p53 non-small cell lung cancer , 2021, Redox biology.

[16]  N. Rizzardi,et al.  Root Extracts of Two Cultivars of Paeonia Species: Lipid Composition and Biological Effects on Different Cell Lines: Preliminary Results , 2021, Molecules.

[17]  Zhongren Xu,et al.  Advances in alkynyl gold complexes for use as potential anticancer agents , 2020, Coordination Chemistry Reviews.

[18]  S. Geremia,et al.  (R)-10-Hydroxystearic Acid: Crystals vs. Organogel , 2020, International journal of molecular sciences.

[19]  G. Kokotos,et al.  Saturated Hydroxy Fatty Acids Exhibit a Cell Growth Inhibitory Activity and Suppress the Cytokine-Induced β-Cell Apoptosis. , 2020, Journal of medicinal chemistry.

[20]  M. Cominetti,et al.  Ru(II)/diclofenac-based complexes: DNA, BSA interaction and their anticancer evaluation against lung and breast tumor cells. , 2020, Dalton transactions.

[21]  Yuanyuan Deng,et al.  Ru(II) Complexes Bearing O, O-Chelated Ligands Induced Apoptosis in A549 Cells through the Mitochondrial Apoptotic Pathway , 2020, Bioinorganic chemistry and applications.

[22]  S. Mbugua,et al.  New Palladium(II) and Platinum(II) Complexes Based on Pyrrole Schiff Bases: Synthesis, Characterization, X-ray Structure, and Anticancer Activity , 2020, ACS omega.

[23]  D. Gibson,et al.  Multiaction Pt(IV) Carbamate Complexes Can Codeliver Pt(II) Drugs and Amine Containing Bioactive Molecules. , 2020, Inorganic chemistry.

[24]  M. Cominetti,et al.  Evaluation of the biological potential of ruthenium(II) complexes with cinnamic acid. , 2020, Journal of inorganic biochemistry.

[25]  N. Calonghi,et al.  Synthesis of Novel Structural Hybrids between Aza-Heterocycles and Azelaic Acid Moiety with a Specific Activity on Osteosarcoma Cells , 2020, Molecules.

[26]  Paul J Dyson,et al.  Recent progress in the development of organometallics for the treatment of cancer. , 2019, Current opinion in chemical biology.

[27]  Anjali,et al.  Optimizing a detection method for estimating polyunsaturated fatty acid in human milk based on colorimetric sensors , 2019 .

[28]  N. Calonghi,et al.  Synthesis of 9-Hydroxystearic Acid Derivatives and Their Antiproliferative Activity on HT 29 Cancer Cells , 2019, Molecules.

[29]  R. De Zorzi,et al.  X-Ray Crystal Structures and Organogelator Properties of (R)-9-Hydroxystearic Acid , 2019, Molecules.

[30]  D. Osella,et al.  A view on multi-action Pt(IV) antitumor prodrugs , 2019, Inorganica Chimica Acta.

[31]  V. Brabec,et al.  Ruthenium coordination compounds of biological and biomedical significance. DNA binding agents , 2018, Coordination Chemistry Reviews.

[32]  C. Turro,et al.  Ru(II) Polypyridyl Complexes Derived from Tetradentate Ancillary Ligands for Effective Photocaging. , 2018, Accounts of chemical research.

[33]  Aprotim Mazumder,et al.  Measuring cell cycle-dependent DNA damage responses and p53 regulation on a cell-by-cell basis from image analysis , 2018, Cell cycle.

[34]  S. King,et al.  "Dressing up" an Old Drug: An Aminoacyl Lipid for the Functionalization of Ru(III)-Based Anticancer Agents. , 2018, ACS biomaterials science & engineering.

[35]  A. Jemal,et al.  Cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.

[36]  Zhe-Sheng Chen,et al.  The development of anticancer ruthenium(ii) complexes: from single molecule compounds to nanomaterials. , 2017, Chemical Society reviews.

[37]  J. Ellena,et al.  Ruthenium(II)/triphenylphosphine complexes: An effective way to improve the cytotoxicity of lapachol , 2017 .

[38]  M. Soliman,et al.  Metal complexes in cancer therapy – an update from drug design perspective , 2017, Drug design, development and therapy.

[39]  R. W. Sun,et al.  Enhanced anti-cancer activities of a gold(III) pyrrolidinedithiocarbamato complex incorporated in a biodegradable metal-organic framework. , 2016, Journal of inorganic biochemistry.

[40]  I. E. El Sayed,et al.  Transition metal complexes of neocryptolepine analogues. Part I: synthesis, spectroscopic characterization, and invitro anticancer activity of copper(II) complexes. , 2015, Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy.

[41]  L. Ji,et al.  Comparison between polypyridyl and cyclometalated ruthenium(II) complexes: anticancer activities against 2D and 3D cancer models. , 2015, Chemistry.

[42]  G. Sheldrick.  SHELXT – Integrated space-group and crystal-structure determination , 2015, Acta crystallographica. Section A, Foundations and advances.

[43]  J. Schellens,et al.  Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy , 2015, Investigational New Drugs.

[44]  V. Moreno,et al.  Influence of PPh₃ moiety in the anticancer activity of new organometallic ruthenium complexes. , 2014, Journal of inorganic biochemistry.

[45]  W. Berger,et al.  NKP-1339, the first ruthenium-based anticancer drug on the edge to clinical application , 2014 .

[46]  Zijian Guo,et al.  Metal-based anticancer chemotherapeutic agents. , 2014, Current opinion in chemical biology.

[47]  V. Grushin,et al.  New, Highly Efficient, Simple, Safe, and Scalable Synthesis of [(Ph3P)3Ru(CO)(H)2] , 2013 .

[48]  I. Ali,et al.  Design and synthesis of thalidomide based dithiocarbamate Cu(II), Ni(II) and Ru(III) complexes as anticancer agents , 2013 .

[49]  J. Jezierska,et al.  Synthesis, characterization and antitumor properties of two highly cytotoxic ruthenium(iii) complexes with bulky triazolopyrimidine ligands. , 2013, Dalton transactions.

[50]  G. Shaw,et al.  Activation of DNA damage response pathways in human mesenchymal stem cells exposed to cisplatin or γ-irradiation , 2011, Cell cycle.

[51]  I. Turel,et al.  Interactions of metal ions with DNA, its constituents and derivatives, which may be relevant for anticancer research. , 2011, Current topics in medicinal chemistry.

[52]  G. Gasser,et al.  Organometallic Anticancer Compounds , 2010, Journal of medicinal chemistry.

[53]  Z. Darżynkiewicz,et al.  Kinetics of the UV‐induced DNA damage response in relation to cell cycle phase. Correlation with DNA replication , 2009, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[54]  W. Berger,et al.  KP1019, A New Redox‐Active Anticancer Agent – Preclinical Development and Results of a Clinical Phase I Study in Tumor Patients , 2008, Chemistry & biodiversity.

[55]  G. Sheldrick.  A short history of SHELX. , 2008, Acta crystallographica. Section A, Foundations of crystallography.

[56]  I. Bratsos,et al.  Ruthenium Anticancer Compounds: Challenges and Expectations , 2007 .

[57]  Jacqueline K Barton,et al.  Methods to explore cellular uptake of ruthenium complexes. , 2007, Journal of the American Chemical Society.

[58]  P. Sadler,et al.  Structure-activity relationships for cytotoxic ruthenium(II) arene complexes containing N,N-, N,O-, and O,O-chelating ligands. , 2006, Journal of medicinal chemistry.

[59]  P. Dyson,et al.  Classical and Non‐Classical Ruthenium‐Based Anticancer Drugs: Towards Targeted Chemotherapy , 2006 .

[60]  G. E. Atilla‐Gokcumen,et al.  Organometallic Compounds with Biological Activity: A Very Selective and Highly Potent Cellular Inhibitor for Glycogen Synthase Kinase 3 , 2006, Chembiochem : a European journal of chemical biology.

[61]  V. Brabec,et al.  DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity. , 2006, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[62]  N. Calonghi,et al.  9-Hydroxystearic acid interferes with EGF signalling in a human colon adenocarcinoma. , 2006, Biochemical and biophysical research communications.

[63]  Erwin P. L. van der Geer,et al.  Controlling ligand substitution reactions of organometallic complexes: tuning cancer cell cytotoxicity. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[64]  R. Casadio,et al.  Histone deacetylase 1: a target of 9-hydroxystearic acid in the inhibition of cell growth in human colon cancer Published, JLR Papers in Press, February 16, 2005. DOI 10.1194/jlr.M400424-JLR200 , 2005, Journal of Lipid Research.

[65]  C. S. Allardyce,et al.  Development of organometallic (organo‐transition metal) pharmaceuticals , 2005 .

[66]  P. Jeggo,et al.  ATM and DNA-PK Function Redundantly to Phosphorylate H2AX after Exposure to Ionizing Radiation , 2004, Cancer Research.

[67]  G. Brusa,et al.  9-Hydroxystearic acid upregulates p21(WAF1) in HT29 cancer cells. , 2004, Biochemical and biophysical research communications.

[68]  M. Nakagaki,et al.  Polymorphic Structure of dl-12Hydroxystearic Acid , 1999 .

[69]  E. Rogakou,et al.  DNA Double-stranded Breaks Induce Histone H2AX Phosphorylation on Serine 139* , 1998, The Journal of Biological Chemistry.

[70]  J C Bailar,et al.  Cancer undefeated. , 1997, The New England journal of medicine.

[71]  T. Stokke,et al.  The retinoblastoma gene product is reversibly dephosphorylated and bound in the nucleus in S and G2 phases during hypoxic stress. , 1996, Experimental cell research.

[72]  M. Nakagaki,et al.  CRYSTAL STRUCTURE OF DL-12-HYDROXYSTEARIC ACID , 1996 .

[73]  K. Nakamoto.  Infrared and Raman Spectra of Inorganic and Coordination Compounds , 1978 .